Calamos Advisors
ACOR

Calamos Advisors’s Acorda Therapeutics ACOR Stock Holding History

Calamos Advisors’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-63
Closed -$201K – 649
2016
Q1 		$201K Sell
63
-11
-15% -$45.7K ﹤0.01% 618
2015
Q4 		$381K Sell
74
-9
-11% -$39.3K ﹤0.01% 595
2015
Q3 		$262K Buy
+83
New +$322K ﹤0.01% 636

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Calamos Advisors's ACOR Position: Q2 2016 in Review

Calamos Advisors sold out of Acorda Therapeutics (ACOR) in Q2 2016, closing a stake of 63 shares — an estimated $201K sold.

Calamos Advisors first reported a position in ACOR in Q3 2015 and held it in 3 quarters. The position peaked at $381K in Q4 2015. 175 funds tracked by Wall St. Rank hold ACOR as of Q2 2016.

  • Calamos Advisors reported no remaining Acorda Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Calamos Advisors sold 63 Acorda Therapeutics shares in Q2 2016, an estimated $201K.
  • Calamos Advisors first reported a position in Acorda Therapeutics in Q3 2015 and held it in 3 quarters.
  • Calamos Advisors's Acorda Therapeutics position peaked at $381K in Q4 2015.
  • 175 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2016.

Based on Calamos Advisors's 13F filing for Q2 2016, filed 26 Jul 2016.